Abstract
Reduced adherence to pharmacotherapy is an important factor that may complicate the long-term management of patients after myocardial infarction. Previous studies have demonstrated that adherence to secondary prevention therapy after acute coronary syndrome remains suboptimal, with substantial variation between medications and patient populations [1,2]. Regular use of prescribed medications is essential for maintaining treatment goals and reducing cardiovascular risk after myocardial infarction [3,4].
The 8-item Morisky Medication Adherence Scale (MMAS-8) is a commonly used standardized instrument for assessing medication adherence and has been evaluated in cardiovascular patient populations [5]. Therefore, assessment of pharmacotherapy adherence in combination with clinical, echocardiographic, and biochemical parameters is of practical importance in the follow-up of patients after myocardial infarction.